Fixed-combination Rx ads limit indication to concomitant-therapy patients

AI-verifiedblockerBinding lawRaised as a question — a person decides

Rule

An advertisement for a prescription drug that is a fixed combination may not recommend or suggest the combination for treatment of patients suffering from a condition amenable to treatment by any single component, rather than limiting the indication to patients for whom the concomitant therapy provided by the fixed-combination drug is indicated, unless the condition is among the uses permitted under 21 CFR 202.1(e)(4).

Check

Confirm the piece is an advertisement for a prescription fixed-combination drug. Identify the advertised indication and confirm it does NOT recommend the drug for a condition treatable by any single active component alone, unless (a) the indication is limited to patients for whom the combined/concomitant therapy is specifically indicated, or (b) the condition falls within the uses permitted under 21 CFR 202.1(e)(4) — i.e., uses contained in labeling accepted in an approved new-drug application or supplement (or new animal drug application/index listing/modification); certain additional uses in commercial use on October 9, 1962 that did not cause the drug to be an unapproved new drug; additional uses in current commercial use that do not cause the drug to be an unapproved new drug; or uses meeting the (e)(4)(iii) standards of general recognition of safety and effectiveness among qualified experts, substantial evidence, or substantial clinical experience. A violation is an ad that promotes the combination broadly for a condition one ingredient alone would treat, without such limitation or (e)(4) basis.

Escalate when

Escalate when it is unclear from labeling whether the promoted condition genuinely requires the combined/concomitant therapy versus being treatable by a single component, or whether the condition qualifies as a use permitted under 21 CFR 202.1(e)(4) (including the (e)(4)(iii) general-recognition/substantial-evidence/substantial-clinical-experience standards). Also escalate if a waiver of this provision has been or may be sought, since the closing proviso of 21 CFR 202.1(e)(6) permits FDA to waive any provision of that paragraph for a specified advertisement by written communication on petition.

Where this comes from

21 CFR 202.1(e)(6)(xii). The highlighted words are quoted exactly; a script confirms they appear in the source before the rule can be published.

… or paraphrase out of context to convey a false or misleading idea. (x) Uses literature, quotations, or references that purport to support an advertising claim but in fact do not support the claim or have relevance to the claim. (xi) Uses literature, quotations, or references for the purpose of recommending or suggesting conditions of drug use that are not approved or permitted in the drug package labeling. (xii) Offers a combination of drugs for the treatment of patients suffering from a condition amenable to treatment by any of the components rather than limiting the indications for use to patients for whom concomitant therapy as provided by the fixed combination drug is indicated, unless such condition is included in the uses permitted under paragraph (e)(4) of this section. (xiii) Uses a study on normal individuals without disclosing that the subjects were normal, unless the drug is intended for use on normal individuals. (xiv) Uses “statistics” on numbers of patients, or counts of favorable results or side effects, derived from pooling data from various insignificant or dissimilar studies in a way that suggests either that such “statistics” are valid if they are not or that they are…

Open the original at these words on ecfr.gov ↗Read our full copy →

Document: 21 CFR 202.1
Version: 2026-09-16 — the link above is pinned to this date, so it shows the text as it stood then
Retrieved: 2026-09-21 from www.ecfr.gov
Fingerprint: a542640a872b3f2702d549e8…

Applies when

Naturepromotional

Productdrug

Rx statusprescription

How this rule was checked

Citation proven by script and passed an independent verifier running on a different model. Not yet confirmed by a human.

Drafted
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the cited text is an operative prohibition, not an example or definition. 21 CFR 202.1(e)(6) states that an advertisement for a prescription drug 'is false, lacking in fair balance, or otherwise misleading ... if it: ... (xii) Offers a combination of drugs for the treatment of patients suffering from a condition amenable to treatment by any of the components rather than limiting the indications for use to patients for whom concomitant therapy as provided by the fixed combination drug is indicated.' The rule statement tracks this, including the (e)(4) permitted-use carve-out.
- Authority correctly 'binding': this is a codified FDA regulation, and (e)(6) items are per se violations ('is false'), not the 'may be' list at (e)(7). Severity 'blocker' is therefore defensible.
- Determinism correctly 'judgment': applying the rule requires assessing whether the promoted condition is 'amenable to treatment by any of the components' and whether the indication is properly limited — a substantive comparison against approved labeling and component pharmacology, not a literal match.
- Atomic: one obligation (limit the fixed-combination indication to concomitant-therapy patients), with a single built-in exception rather than a bundled second requirement.
- Locator is accurate; the quoted language is verbatim from (e)(6)(xii).
- Overstated on scope in two respects. (1) The chapeau of (e)(6) limits the provision to 'An advertisement for a prescription drug'; the rule as written ('may not be promoted') reaches any fixed-combination drug in any promotional context, including OTC products and promotional labeling, which this excerpt does not establish. (2) The quote is truncated before the source's own limitation, 'unless such condition is included in the uses permitted under paragraph (e)(4) of this section' — the rule's parenthetical exception ('or the condition is otherwise a permitted use') is therefore not visible in the evidence a reviewer is shown, and is stated more vaguely than the source's cross-reference.
- The 'escalate when' and 'check' fields are consistent with the source and actionable for a reviewer.
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — revise
claude-opus-5 · 2026-09-21
Reviewer's reasons
- Supported: the quote is verbatim item (xii) in the operative list governed by the chapeau 'An advertisement for a prescription drug is false, lacking in fair balance, or otherwise misleading, or otherwise violative of section 502(n) of the act, among other reasons, if it:'. It is a binding prohibition, not an example or definition, and the rule statement tracks it closely.
- Overstated on scope: (e)(6) applies only to 'an advertisement for a prescription drug'. The rule says 'advertised or promoted' and applies_when specifies only product-type 'drug', so it would fire on OTC products and on promotional labeling outside the reach of 21 CFR 202.1.
- The check misdescribes the (e)(4) carve-out as 'pre-1962 grandfathered uses'. The source shows (e)(4) also covers uses in labeling accepted in an approved NDA/supplement or new animal drug index listing, additional uses in current commercial use, and uses generally recognized as safe and effective or supported by substantial evidence or substantial clinical experience under (e)(4)(iii). The narrow gloss would cause reviewers to reject a valid carve-out based on approved labeling.
- Escalate condition omits the waiver proviso closing (e)(6): 'any provision of this paragraph shall be waived with respect to a specified advertisement as set forth in a written communication from the Food and Drug Administration on a petition for such a waiver'. Relevant given blocker severity.
- Authority 'binding' is correct: 21 CFR 202.1 is a codified regulation.
- Determinism 'judgment' is correct: whether a condition is 'amenable to treatment by any of the components' and whether the indication is adequately 'limited' to concomitant-therapy patients turns on clinical and impression judgment, not presence/absence or literal match.
- Atomic: one prohibition plus two exceptions that are integral conditions of the same requirement, not independently checkable obligations.
- Locator 21 CFR 202.1(e)(6)(xii) matches the quoted subparagraph exactly; 'blocker' is defensible because (e)(6) deems such an advertisement false/misleading and violative of section 502(n).
Revised by the drafter
claude-sonnet-5 · 2026-09-21
Independent verification — pass
claude-opus-5 · 2026-09-21
Reviewer's reasons
- The quote appears verbatim in the source as item (xii) of the enumerated list introduced by '(6) Advertisements that are false, lacking in fair balance, or otherwise misleading. An advertisement for a prescription drug is false ... among other reasons, if it:'. This is an operative prohibitory list, not an example, definition, or preamble summary, so the rule statement follows directly from the cited text.
- Not overstated. Unlike paragraph (e)(7) ('may be false... misleading'), paragraph (e)(6) declares such advertisements to be false/lacking fair balance/violative of section 502(n), so rendering it as a flat prohibition ('may not recommend or suggest') is faithful. The (e)(4) proviso is carried over intact rather than dropped. Narrowing 'a combination of drugs' to fixed-combination prescription products is a narrowing, not a broadening, and is consistent with the provision's own reference to 'the fixed combination drug'.
- Atomic. There is a single checkable obligation: the advertised indication for a fixed-combination product must be limited to patients for whom the concomitant therapy is indicated. The (e)(4) clause is a built-in exception to that same obligation, not an independently checkable second requirement.
- Determinism 'judgment' is correct: deciding whether a promoted condition is 'amenable to treatment by any of the components' alone, and whether the indication is properly limited to concomitant-therapy patients, turns on clinical/labeling interpretation, not on literal presence or absence of a string.
- Authority 'binding' is correct — 21 CFR 202.1 is a codified FDA regulation implementing section 502(n) of the act.
- applies_when (promotional, drug, prescription) matches the source's own framing, 'An advertisement for a prescription drug'. The fixed-combination limitation is carried in the rule statement and first step of the check, which is the appropriate place for it given the facet vocabulary.
- Severity 'blocker' is defensible: violation renders the advertisement false/misleading and the drug misbranded under section 502(n); it is an indication-scope defect that cannot be cured by added disclosure.
- Locator 21 CFR 202.1(e)(6)(xii) is correct for the quoted text.
- The check's expansion of the (e)(4) exception (approved NDA/supplement labeling, new animal drug application/index listing/modification, pre-October 9, 1962 commercial uses, current commercial uses not creating an unapproved new drug, and the general-recognition/substantial-evidence/substantial-clinical-experience standards) is traceable to the (e)(4) material reproduced in the excerpt. The excerpt's own subparagraph lettering is internally inconsistent (the general-recognition criteria appear under an item labeled '(ii)' while cross-references in the text point to '(e)(4)(iii)'); the check follows the cross-reference used in the regulation itself, which is acceptable.
- The escalation note about waivers is grounded in the closing proviso of paragraph (e)(6) quoted in the source, which expressly provides for waiver of any provision of that paragraph by written FDA communication on petition.